• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KLDO

    Kaleido Biosciences Inc.

    Subscribe to $KLDO
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: kaleido.com

    Peers

    $EVLO

    Recent Analyst Ratings for Kaleido Biosciences Inc.

    DatePrice TargetRatingAnalyst
    1/31/2022$11.00 → $3.00Buy
    Chardan Capital
    11/12/2021$15.00 → $11.00Buy
    Chardan Capital
    11/3/2021$25.00 → $22.00Market Outperform
    JMP Securities
    10/19/2021$3.00Equal-Weight → Underweight
    Morgan Stanley
    See more ratings

    Kaleido Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Van Hylckama Vlieg Johan covered exercise/tax liability with 2,087 units of Restricted Stock Units, decreasing direct ownership by 31% to 4,620 units

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      3/2/22 4:09:49 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Korn Jerald covered exercise/tax liability with 2,046 units of Restricted Stock Units, decreasing direct ownership by 31% to 4,517 units

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      3/2/22 4:05:37 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Van Hylckama Vlieg Johan

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:18:21 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Long Alison S

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:15:22 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Korn Jerald

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:12:55 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Duke William E.

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:11:18 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Menichella Daniel L

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:09:32 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Long Alison S

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      12/16/21 5:18:49 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Long Alison S

      3 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      12/16/21 5:16:33 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Van Hylckama Vlieg Johan

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      9/2/21 4:23:25 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Kaleido Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $3.00 from $11.00 previously

      1/31/22 9:22:16 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $11.00 from $15.00 previously

      11/12/21 7:22:49 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities reiterated coverage on Kaleido Biosciences with a new price target

      JMP Securities reiterated coverage of Kaleido Biosciences with a rating of Market Outperform and set a new price target of $22.00 from $25.00 previously

      11/3/21 7:54:29 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kaleido Biosciences downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Kaleido Biosciences from Equal-Weight to Underweight and set a new price target of $3.00

      10/19/21 7:01:24 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley reiterated coverage on Kaleido Biosciences with a new price target

      Morgan Stanley reiterated coverage of Kaleido Biosciences with a rating of Equal Weight and set a new price target of $12.00 from $13.00 previously

      3/15/21 8:09:46 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley reiterated coverage on Kaleido Biosciences with a new price target

      Morgan Stanley reiterated coverage of Kaleido Biosciences with a rating of Equal-Weight and set a new price target of $12.00 from $13.00 previously

      3/8/21 10:55:30 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Canaccord Genuity resumed coverage on Kaleido Biosciences with a new price target

      Canaccord Genuity resumed coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $19.00

      3/4/21 7:51:22 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Kaleido Biosciences with a new price target

      Piper Sandler initiated coverage of Kaleido Biosciences with a rating of Overweight and set a new price target of $19.00

      2/9/21 6:36:18 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care